China SBR plant capacity is expected to increase from 1.630 MMTPA in 2014 to 1.730 MMTPA in 2019, at a CAGR of 1.2%. State owned companies dominate the Styrene-Butadiene Rubber (SBR) sector in China. The major companies in the region are China National Petroleum Corporation, China Petroleum & Chemical Corporation, Fujian Meizhouwan Chlor-Alkali Chemical Industry Co., Ltd., TSRC Corporation, Tianjin Lugang Petroleum & Rubber Engineering Company.
GlobalData’s Styrene-Butadiene Rubber (SBR) Industry Outlook in China to 2019 report provides historical and forecasted market sizes, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading producers to provide comprehensive coverage of all parameters of the industry.
This report includes:
- Comprehensive information of all active and planned Styrene-Butadiene Rubber plants/projects in China
- Capacity forecasts to 2019 with details like process, technology, operator and equity
- SBR industry supply scenario and market dynamics in China from 2005 to 2019
- Plant capacity growth and installed plant capacity by production process and technology
- Trade balance data from 2005 to 2019
- Import and export data and net exports and imports as a percentage of demand
Get first-hand information on market size, trends, growth, competitive landscape, and future outlooks.
Oncology is the prime area for gene therapy development due to its high prevalence and genetically driven pathophysiology. There are 266 pipeline gene therapies in active development for oncology, more than twice that of central nervous system disorders, which is the second-largest therapy area. Furthermore, oncology also accounted for 64% of gene therapy clinical trials between 1989 and 2012. The reason behind such a large overall pipeline is the potential for these therapies to develop strong drugs by targeting diseases on a genetic level. Although no products have yet fulfilled this promise, developers expect this in the future.
CBR Pharma Insight’s Gene Therapy: A Diverse Range of Technologies with a Promising Long-Term Outlook report provides analysis of the product pipeline, including details on the relative clinical and commercial success of currently marketed products as well as the current competitive landscape, with a breakdown of companies actively involved in this space.
Key questions answered in this report:
- Why do gene therapies still occupy only a minimal market share in their respective indications?
- What can be learned from the therapies that have already hit the market?
- What are the relative advantages/disadvantages of each vector type and which hold the most promise?
- What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?
- In which therapy areas have the highest level of R&D activity for gene therapies?
- At which stage of development do the majority of pipeline gene therapies reside?
- What is the proportion of the pipeline occupied by each intervention and vector type overall?
- What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?
How do gene therapies fit into the overall portfolios of the Big Pharma Companies, find out more.
South Africa’s climatic conditions are highly suited to CPV technology, due to high Direct Normal Irradiance (DNI) rates throughout most of the country and the availability of vast acres of land. South Africa’s first CPV plants were commissioned in 2010 with a combined capacity of 0.2 MW, but the country now has the world’s third-largest installed CPV capacity, despite having an installed Photovoltaic capacity of 1.5 GW. While South Africa’s CPV installed capacity is expected to hit 193.3 MW by 2020, China will lead the global markets with 582.3 MW by 2020. China remains the fastest growing CPV market in the world, high DNI concentration levels in the western part of the country, combined with China’s manufacturing capacity, has made it home to the largest existing CPV plants and the highest number of upcoming large-scale plants.
GlobalData’s Concentrated Photovoltaic (CPV) Market, Update 2015 – Global Market Size, Competitive Landscape and Key Country Analysis to 2020 report provides analysis of historic and forecast statistics for cumulative and annual concentrated photovoltaic (CPV) capacity and annual electricity generation from 2006 to 2020.
This report includes:
- Market share of manufacturers globally and in each of the key countries
- Major policies and regulations affecting the concentrated photovoltaic market
- Key growth drivers and challenges related to the global CPV market
China will still represent a major part of the global installed CPV capacity in 2020, where does South Africa stand? Find out more.
Energy world is expected to witness the start of operations of 64 FPSOs over the course of the next five years giving a strong push to offshore oil and gas production. However, weak oil prices may discourage oil and gas companies from moving ahead on their final investment decisions. This could affect the start-up of several planned FPSOs in the world. Brazil has been at the forefront of industry, with the country already deploying 17 FPSOs from 2009 to 2014. Furthermore, Brazil is expected to deploy another 25 FPSOs by 2019. Recently, Brazil has made hundreds of discoveries in its offshore region, especially in the sub-salt region, and FPSOs are a convenient and cost effective way to develop the fields containing these discoveries.
Our latest Global FPSO Industry Outlook report provides detailed data of FPSOs that were brought online from 2009 to 2014 by key regions in the world, with forecasts up to 2019.
This report includes:
- Forecast of FPSOs that will be brought online by 2019, by key countries and operators
- Details on the major expansions and planned projects up to 2019
- Recent FPSO developments, tenders and contracts by key regions
- Get more insights on how Brazil leads record FPSO deployments, in spite of deteriorated project economics.